Impact BioMedical announces 1-for-12.62 reverse split for Zoar merger
AI Summary
Impact BioMedical announced a reverse stock split to pursue its Zoar merger.
1-for-12.62 is the announced reverse stock split ratio.
Zoar Ltd. was previously known as Dr. Ashley’s Ltd.
Impact BioMedical Inc. (NYSE American: IBO) announced a 1-for-12.62 reverse stock split (consolidating shares into fewer outstanding shares) as it pursues completion of its merger with Zoar Ltd., previously known as Dr. Ashley’s Ltd.
The information on this website is generated using AI and we cannot guarantee its accuracy.
Please use it as reference information only.